Drug Profile
Research programme: ion channel blockers - Zealand Pharma
Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Class Peptides
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Unspecified in Denmark
- 16 Apr 2018 Preclinical trials in Undefined indication in Denmark (unspecified route) (Zealand Pharma pipeline, April 2018)